A multidrug-resistant parasite lineage that has become dominant in Cambodia, with spread to parts of Thailand and Laos, has now spread to southern Vietnam, where it has been linked to an alarming number of treatment failures in patients who were given the nation's first-line treatment.
The Saudi Arabian Ministry of Health (MOH) announced a new case of MERS-CoV yesterday, in a patient who had contact with camels, a known risk factor for contracting the virus.
A new study by researchers with the US Centers for Disease Control and Prevention indicates that availability of antifungal susceptibility testing (AFST) at US hospitals has improved in recent years, but substantial gaps remain.
With resistance emerging to a limited set of treatment options, new drugs for invasive fungal infections are desperately needed.
Also, the CDC said C auris has been isolated from 110 more patients hospitalized in three affected states.
Canadian researchers are reporting the first case of the drug-resistant fungal pathogen Candida auris in Canada.
In the wake of new laws and tighter federal oversight, the FDA has done more than 400 inspections, sent 150 warning letters, and overseen 125 recalls.
A new fluoroquinolone antibiotic, delafloxacin (Baxdela), for acute bacterial skin and skin structure infections (ABSSSI) in adults gained approval yesterday from the US Food and Drug Administration (FDA), according to Melinta Therapeutics, the manufacturer.
In today's Morbidity and Mortality Weekly Report, investigators from the Centers for Disease Control and Prevention (CDC) and several state health departments say a total of 77 clinical cases of the emerging multidrug-resistant fungus Candida auris have now been reported from seven states.
A novel antifungal drug has shown in vitro activity against the emerging fungal pathogen Candida auris, researchers report in Antimicrobial Agents and Chemotherapy.
